MAA
ADVM

Managed Account Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Managed Account Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-24
Closed -$10K – 3008
2015
Q1 		$10K Buy
+24
New +$10.1K ﹤0.01% 2820

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Managed Account Advisors's ADVM Position: Q2 2015 in Review

Managed Account Advisors sold out of Adverum Biotechnologies (ADVM) in Q2 2015, closing a stake of 24 shares — an estimated $10K sold.

Managed Account Advisors first reported a position in ADVM in Q1 2015 and held it in 1 quarter. The position peaked at $10K in Q1 2015. 96 funds tracked by Wall St. Rank hold ADVM as of Q2 2015.

  • Managed Account Advisors reported no remaining Adverum Biotechnologies position as of Q2 2015 after selling out during the quarter.
  • Managed Account Advisors sold 24 Adverum Biotechnologies shares in Q2 2015, an estimated $10K.
  • Managed Account Advisors first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 1 quarter.
  • Managed Account Advisors's Adverum Biotechnologies position peaked at $10K in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.